NASDAQ: FRNMFreenome Inc Stock
$15.75-0.24 (-1.5%)
Updated Sep 9, 2026
FRNM Price
$15.75
Fair Value Price
N/A
Market Cap
$1.69B
52 Week Low
$9.95
52 Week High
$17.18
P/E
-1.47x
P/B
-1.27x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$34.63M
Earnings
-$762.63k
Gross Margin
N/A
Operating Margin
-802.05%
Profit Margin
-818.9%
Debt to Equity
-0.3
Operating Cash Flow
-$907k
Beta
0.1
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
FRNM Overview
Freenome is an early cancer detection company developing blood-based screening tests to identify cancer in its earliest, most treatable stages. The company's proprietary multiomics discovery platform analyzes circulating cell-free DNA methylation patterns at single-base resolution alongside additional biomarkers to detect multiple cancers. Freenome's first commercial-stage test, SimpleScreen CRC for colorectal cancer, is under review by the U.S. Food and Drug Administration (FDA).
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine FRNM's potential to beat the market
- FRNM doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Diagnostic & Research
Industry Rating
B
FRNM
RankedUnranked of 39
RankedUnranked of 39
Be the first to know about important FRNM news, forecast changes, insider trades & much more!
FRNM News
Overview
Due Diligence Score
–
Industry Average (29)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how FRNM scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
FRNM is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
FRNM is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
FRNM's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more FRNM due diligence checks available for Premium users.
Valuation
FRNM fair value
Fair Value of FRNM stock based on Discounted Cash Flow (DCF)
Price
$15.75
Fair Value
$0.10
Overvalued by
15,603.92%
FRNM is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
FRNM price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.47x
Industry
12.41x
Market
40.8x
FRNM price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-1.27x
Industry
4.3x
FRNM's financial health
Profit margin
Revenue
$0.0
Net Income
-$114.9k
Profit Margin
0%
FRNM's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
FRNM's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$85.8M
Liabilities
$7.1M
Debt to equity
-1.12
FRNM's short-term assets ($155.00M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
FRNM's long-term liabilities ($316.46M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
FRNM's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
FRNM's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$129.8k
Investing
$8.2M
Financing
$0.0
FRNM's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
FRNM vs Diagnostic & Research Stocks
Freenome Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.